Effect of metformin on the epigenetic age of peripheral blood in patients with diabetes mellitus

15Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Background: Metformin has been proven to have an antiaging effect. However, studies on how metformin affects global epigenetic regulation and its effect on the epigenetic clock in diabetes mellitus (DM) patients are limited. This study aims to investigate the impact of metformin on the epigenetic age in subjects with type 2 DM. Results: We collected the peripheral blood of the metformin group and the no-metformin group of the 32 DM patients. Three previously established epigenetic clocks (Hannum, Horvath, and DNAmPhenoAge) were used to estimate the epigenetic age acceleration of the two groups. We defined biological age acceleration for each group by comparing the estimated biological age with the chronological age. Results were presented as follows: 1) all three epigenetic clocks were strongly correlated with chronological age. 2) We found a strong association between metformin intake and slower epigenetic aging by Horvath’s clock and Hannum’s clock. Conclusions: Here, we found an association between metformin intake and slower epigenetic aging.

Cite

CITATION STYLE

APA

Li, M., Bao, L., Zhu, P., & Wang, S. (2022). Effect of metformin on the epigenetic age of peripheral blood in patients with diabetes mellitus. Frontiers in Genetics, 13. https://doi.org/10.3389/fgene.2022.955835

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free